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The Human Papillomavirus (HPV) is one of the most prevalent sexually 
transmitted diseases among American men and women. When first licensed by the 
United States Food and Drug Administration (FDA), the HPV vaccine was originally 
only approved for use in females ages 9-26 years. Promotional communications reflected 
this, using messaging strategies that effectively positioned the vaccine as a “women’s 
vaccination.” In 2010, the FDA approved the HPV vaccine for use in males ages 9-26, 
though advertising and marketing of the vaccine for this new population was limited. 
This study evaluated males’ knowledge of and attitudes toward HPV and the HPV 
vaccine, as well as message tactics for promotion of the HPV vaccine to male 
populations. Using an online survey and a convenience sampling technique, this study 
reached a young, highly educated sample of males within the “catch up” program age 
range. The results of the study indicated a basic understanding o HPV, but a limited 
understanding of the health-risks associated with the disease. Communication efforts 
using fact-based tactics were found to be the most effective at persuading males to seek 
vaccination. 
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1.0 Introduction 
More than 20 million people in the United States are currently afflicted with 
Human Papillomavirus (HPV), and it is assumed that most people will contract the 
disease in their lifetime, perhaps even unknowingly. Though the human body usually 
fights off the disease naturally, infected persons are at a greater risk for several types of 
cancers. A vaccine against the disease has been developed, tested, and ultimately proven 
safe over the course of a decade. Only half of the population, however, has been directly 
informed that the vaccine is available. 
The initial release of the HPV vaccine was announced with a national advertising 
campaign targeted at females, drawing a heavy connection between HPV and cervical 
cancer. This was due to the fact that the vaccine was initially approved only for use in 
females, however, none of the messages released in the initial campaign mentioned the 
fact that HPV is a cause of concern for both men and women. This initial marketing 
strategy was effective for increasing vaccine uptake among women, but it may have been 
detrimental to the later approval of the vaccine program for males. Because of this initial 
campaign, HPV may face a branding issue as a “girl’s” vaccine. 
The high prevalence of human papillomavirus increases the importance of 
ensuring both females and males are aware of HPV and the associated health risks, as 
well as the potential benefits of vaccination. The lack of information targeted toward 
males may contribute to low vaccine uptake among males in the “catch up” program age 
range who are responsible for making their own personal health decisions. Deciding 





2.0 Literature Review 
The Human Papillomavirus (HPV) is a group of more than 150 related viruses, 40 
of which can be sexually transmitted (Lamming & Beckett, 2011). The vast amount of 
HPV virus types makes it one of the most prevalent sexually transmitted diseases in the 
United States; nearly all sexually active individuals will contract HPV at some point in 
their lives. Fourteen of the sexually transmitted HPVs are high-risk, and can cause genital 
warts and cervical cancer in women. HPV can also be detrimental to men’s health, 
causing penile and anal cancers in addition to genital warts. HPV is most commonly seen 
in young adults (late teens – early 20s), but because the body often naturally fights off 
HPV before significant health problems arise, the majority of people who contract the 
disease are unaware of it ((“HPV vaccine for preteens and teens”, 2014). 
Two HPV vaccinations have been developed in the last 10 years. Cervarix is a 
bivalent vaccine licensed for use in females who are at least 10 years old and protects 
against HPV types 16 and 18. Gardasil is a quadrivalent vaccine licensed for use in 
individuals that are at least 9 years old and protects against types 16, 18, 6, and 11 
(Lamming & Beckett, 2011). HPV types 6 and 11 can cause genital warts, but do not 
cause cervical cancer. The additional protection Gardasil provides against HPV types that 
can cause genital warts makes it an ideal option for men who are interested being 
vaccinated. Because the initial purpose and focus of both Cervarix and Gardasil was to 
protect women against cervical cancer, the second most common cancer worldwide, 
neither vaccine was immediately made available to men. In the last three years however, 
Gardasil has been approved for use in males to prevent genital warts. 
When Gardasil and Cervarix were first approved by the U.S. Food and Drug 
Administration (FDA) public reaction was not immediately positive. Both vaccines were 
intended to be administered in 3 doses over the course of 4-6 months (“HPV vaccine for 
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preteens and teens”, 2014), and most vaccination programs were focusing immunization 
efforts on girls age 12-13, because immunization is most effective in individuals that are 
not yet sexually active. A “catch-up” campaign was simultaneously established for 
women over the age of 14. Table 1 provides an example of the age divisions in an initial 
HPV immunization program (Lamming & Beckett, 2011). Common side effects after 
vaccination include pain at the site of the injection, fever, dizziness, and nausea (“HPV 
vaccine for preteens and teens”, 2014) The CDC continues to monitor side effects related 
to HPV vaccinations using the Vaccine Adverse Event Reporting System (VAERS), 
Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment Project 
(CISA). An 8-year study of health events related to HPV vaccination (reported to 
VAERS) was published in 2014, showing that approximately 92% of reports were non-
serious (Centers for Disease Control and Prevention, 2015).  
 
Table 1: Vaccination age ranges. 
Females aged 
0-12 years 
Cervarix is licensed for individuals from 10 years old 
Gardasil is licensed for individuals from 9 years old 
Vaccination is not routinely recommended for those aged 9–12 years 
Females aged 
12-13 years 
HPV vaccination is recommended for all girls at 12–13 years of age as part of 
routine childhood immunization schedule 
Females aged 
14 to <18 
years 
For most primary care organizations, the catch-up campaign is complete and 
therefore the only routine vaccination in all but three trust areas will be the 
school year 8 cohort, i.e. those aged between 12–13 years 
Females aged 
18 years or 
over 
Vaccination is not routinely recommended for those aged 18 years or over. 
Gardasil is licensed for women aged 9–45 years. Cervarix is licensed for those 






Where a female in the target cohort aged over 12 and under 18 years presents 
with an inadequate vaccination history, every effort should be made to clarify 
what doses she has had. A female who has not completed the schedule should 
complete the vaccination course at the minimum interval where possible. 
Females coming to the UK from overseas may not have been offered protection 
against HPV in their country of origin and should be offered vaccination where 
appropriate 
 “Cohort to be vaccinated under the HPV immunization programme” table extracted 
from “A brief guide to human papillomavirus vaccination” (Lamming & Beckett, 2011) 
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Negative perceptions and acceptance over both the Gardasil and Cervarix 
vaccinations stemmed from concerns over the general safety of the vaccine and 
anticipated side effects, changes in sexual behavior among vaccinated individuals, and 
the financial cost of the vaccine. 
The HPV vaccine is designed as a preventative measure, and as such is meant to 
be administered to individuals before they become sexually active. Because 
approximately 37% of males and 28% of females admit to having sexual intercourse by 
the ninth grade (Blumenthal, et al., 2012)), it has been suggested that HPV vaccination 
regimens be directed at younger adolescent populations.  
 
2.1 Perceptions and Acceptance 
Many sexually active adolescents have a limited understanding of the Human 
Papillomavirus as a common sexually transmitted infection, and as such, many 
adolescents report a low perceived personal risk of contracting HPV. The lack of 
knowledge in regards to sexual health often contributes to hesitance in adolescent 
acceptance of the HPV vaccine (Blumenthal, et al., 2012)). In several studies of 
adolescent understanding and acceptance of HPV vaccination, teens reported that 
healthcare providers are an important and credible source of information. Other important 
sources for seeking advice on sexual health include peers and parents. 
Studies of parental attitudes toward vaccination derived similar predictors of 
vaccine acceptance as studies of intents to be vaccinated among adolescent males and 
females. Parental views of the severity of HPV susceptibility, social norms (vaccine 
acceptance by important others) and normative beliefs (vaccine acceptance by other 
mothers) are common predictors of vaccine acceptability (Marlow, Waller & Wardle, 
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2007). Education level, history of sexually transmitted infections (STIs) and level of 
parental monitoring among peers are additional factors that can predict intents to have 
children vaccinated (Rosenthal et al., 2008).  
Numerous studies have been conducted to examine factors for HPV vaccine 
acceptances – several of which were conducted prior to the approval of the vaccine for 
males. In a review of 28 such studies, reviewers (Brewer & Fazekas 2007) found that key 
factors for vaccine acceptance or rejection were widely universal and could be reasonably 
predicted. Factors of higher acceptability, for instance, include perceived vaccine 
effectiveness, recommendation of the vaccine program by a healthcare provider, high 
perceived risk of HPV infection, and a belief that key “others” (parents, partners) also 
view the vaccine favorably. Factors contributing to negative vaccine acceptability include 
low perceived risk of HPV infection (Brewer & Fazekas 2007). Convincing men to 
commit to the vaccination program has proven difficult for several reasons, and factors 
contributing to male intents to be vaccinated vary based on age, sexual preferences, and 
current understanding of HPV and its associated risks. 
Major factors contributing to vaccine acceptance and intent to vaccinate include: 
education, perceived risk, current relationship status, general and specific concerns over 
vaccine safety, moral concerns regarding the promotion of promiscuous behavior, and 
source of the vaccine recommendation.  
 
2.1.1 Education 
Lack of knowledge is often cited as a reason for uncertainty in regards to 
vaccination; many males note that they need additional information before making a 
decision about vaccination (Forster, Marlow, Wardle, Stephenson & Waller, 2012). 
Studies among women showed that individuals who were less likely to report acceptance 
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of the HPV vaccine had limited knowledge of HPV and the health risks associated with 
the disease (Crosby, DiClemente, Salazar, Nash & Younge, 2011). In addition, many 
sexually active adolescents have a limited understanding of the Human Papillomavirus as 
a common sexually transmitted infection, and as such, many adolescents report a low 
perceived personal risk of contracting HPV. The lack of knowledge in regards to sexual 
health often contributes to hesitance in adolescent acceptance of the HPV vaccine 
(Blumenthal, et al., 2012). Among students in surveyed in Turkey, early diagnosis of 
cancer was deemed important but knowledge of cervical cancer prevention was limited 
(Zeliha, 2014). Individuals surveyed in an Australian study were largely unable to 
identify HPV as the cause of cervical cancer. Among those participants in the study that 
were aware of HPV as a cause of cervical cancer, women were more likely to be 
knowledgeable than men (Marshall, Ryan, Roberton & Baghurst, 2007). 
Studies conducted by Merck, the manufacturer of Gardasil, demonstrated the 
vaccine has a 90% efficacy in preventing external genital lesions caused by HPV in men 
(Chitale, 2009), however, men that are less likely to report acceptance of the vaccine 
have little to no knowledge of this information (Crosby et al., 2011). Additionally, 
because incidences of penile and anal cancer are less common than incidences of cervical 
cancer, and because HPV related cancers often occur much later for men than for women 
(Chitale, 2009), young men are less likely to be informed of HPV and HPV related health 
risks. 
Medical staff in a clinic study noted that mothers who had previously received an 
abnormal Pap test, or knew someone who had, were more likely to request the HPV 
vaccine for their daughters (Javanbakht et al., 2012). In another study of male acceptance 
of the HPV vaccine, fathers were specifically cited as less likely to be knowledgeable 
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about the vaccine, and thus would be less aware of their child’s intent to be vaccinated 
(Gutierrez et al., 2013). 
 
2.1.2 Perceived Risk 
A major factor contributing to negative vaccine acceptability is low perceived risk 
of HPV infection (Brewer & Fazekas 2007). Low perceived risk of contracting HPV 
correlates with a low intent to vaccinate (Marshall, et al., 2007). Lack of education and 
knowledge about the prevalence of HPV and the health risks associated with HPV may 
contribute to the low perceived risk among both males and parents making the decision to 
vaccinate. Additionally, because HPV is regarded as a personal risk, it also lacks a source 
of authority in mandating vaccination, which might also contribute to the diminished 
perception of risk of contraction. Unlike vaccinations that are required for school, the 
HPV vaccine has no source of authority which encourages vaccination of children in the 
recommended age range (Javanbakht et al., 2012). 
HPV vaccination among males also faces a barrier in distribution of 
responsibility. Because the vaccine has been available for females (and has primarily 
been promoted as a “girl’s vaccine” for several years) some male populations do not feel 
the need to be vaccinated, as they are protected from contracting HPV by their vaccinated 
partner. In one study, partner vaccinations alleviated the responsibility males felt to be 
vaccinated. Participants indicated that if their partner were to be vaccinated, this would 
protect both parties (Gutierrez et al., 2013). This thought process has been demonstrated 
in studies of both heterosexual and MSM (men who have sex with men) male 
populations.  
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Current level of sexual activity correlates with perceived risk as well. Males that 
are not sexually active, or that do not perceive any risk of contracting HPV in their 
current sexual relationship show a low intent to vaccinate (Forster, et al., 2012). 
Additionally, age has been shown to influence perceived risk. Age as a cultural 
factor impacts decisions to vaccinate among some male student populations; students at a 
Turkish university believed they were too young to receive the vaccine (Zeliha, 2014). 
In a study of psychosocial motivational factors correlating to intent to be 
vaccinated in male populations, researchers found that individuals who were currently 
sexually active and who had multiple sexual partners were more likely to report a positive 
acceptance of the Gardasil vaccine and a higher intent to be vaccinated (Crosby et al., 
2011). Additionally, men with a large number of lifetime female sexual partners are more 
likely than men currently in committed relationships to show vaccine acceptance (Ferris 
et al., 2009). 
 
2.1.3 Vaccine Safety Concerns 
Mistrust of vaccinations in general is a common reason cited among males who 
choose not to be vaccinated (Forster, et al., 2012). The possibility of adverse side effects 
is also frequently cited as a reason for low intent to vaccinate (Zeliha, 2014), and 
uncertainty about vaccine side effects in general is commonly identified as a main 
vaccination concern (Marshall et al., 2007). 
Vaccine safety is a concern among healthcare professionals as well as parents 
(Marshall et al., 2007); however, most healthcare professionals have now accepted the 
HPV vaccine as safe. Personal beliefs in vaccination ethics and necessity also affect 
parental consent; among some parents there exists an assumption that children past a 
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certain age do not need vaccinations. This limits the ability of healthcare professionals to 
promote vaccine programs (Javanbakht et al., 2012).  
Misconceptions also surround no-cost vaccine programs. Some parents believe 
that no and low cost vaccine programs are only available for young children and infants 
(Javanbakht et al., 2012). Additionally, HPV vaccination programs have seen limited 
support. Genital warts, the most commonly cited health risk associated with HPV for 
males, is non-fatal, and while it may have a high monetary and mental cost for infected 
individuals, it is not seen as a cost-effective reason for supporting male HPV vaccination 
programs (Schwartz, 2010). 
While tenderness of the vaccination site, nausea, fever and dizziness are also 
noted as a common side effects of receiving the HPV vaccine, few studies assessed 1) the 
child’s feelings about receiving the vaccination, or 2) parental considerations of the 
child’s feelings. In only one study, the child’s feelings about receiving a 3 shot series was 
shown to influence acceptability and intents among parents (Rosenthal et al., 2008). 
 
2.1.4 Moral Concerns 
Unlike other diseases for which vaccination is required, contraction of HPV is 
dependent upon an individual’s personal choices and behavior. For this reason, many 
parents hesitate to have their children vaccinated at the recommended age. Parents across 
numerous studies expressed concern that having their child vaccinated for HPV would 
encourage the child to engage in sexual activity at a younger age.  
In early studies (conducted prior to the vaccine being approved for use in males), 
mothers showed enthusiasm for having their daughters vaccinated, but expressed 
hesitation over concerns that the vaccine would condone sexual behavior at an earlier age 
(Marlow et al., 2007). In one study, Australian mothers were more concerned than fathers 
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that HPV vaccination would condone promiscuous behavior (Marshall et al., 2007). A 
quote from New Scientist in 2005 summarizes moral concerns: “Giving the HPV vaccine 
to young women could be potentially harmful, because they may see it as a licence to 
engage in premarital sex” (MacKenzie, 2005). 
Misunderstandings over the HPV vaccine being preventative, rather than curative, 
contribute to parental assumptions that having their children vaccinated will promote and 
condone sexual activity (Javanbakht et al., 2012). While health care providers have 
largely accepted HPV vaccination programs, parents hesitate at the young age 
recommendation for vaccination (Marlow et al., 2007). A 2012 study found that while 
concerns over the possible promotion of sexual activity were widespread, vaccination of 
girls in the recommended age range did not increase sexual activity (Bednarczyk, Davis, 
Ault, Orenstein, Omer, 2012).  
In addition, some parents feel they are unprepared to discuss sex with their 
children at such a young age, and that having their children vaccinated will force them to 
have discussions prematurely (Javanbakht et al., 2012). In one Australian study, a mean 
age of approximately 13 years was identified as appropriate for discussions of HPV 
vaccination, and a mean age of 14 years was identified as appropriate for starting the 
vaccination treatment (Marshall et al., 2007). 
 
2.1.5 Source of Vaccine Recommendation 
The source of vaccine recommendation plays an important role in affecting male 
and parental attitudes and intents toward vaccination. Until 1997, when pharmaceutical 
companies began marketing product information directly to consumers, patients’ primary 
source of health information came from a healthcare provider (Grantham, Ahern & 
Connolly-Ahern, 2011). Success for HPV vaccination programs is dependent upon three 
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tiers of acceptance: health care providers’, from whom recommendations are needed; 
parents, from whom permission is often required; and individuals’ (Zimet, 2005). Clinic 
staff from a 2009 study noted friends and family as effective at reinforcing HPV beliefs, 
notably beliefs that the vaccine is not necessary because it is not a mandatory vaccine 
required by schools (Javanbakht et al., 2012).  
Males obtain their knowledge of HPV and the HPV vaccination from a variety of 
messaging sources. These include: health education classes, television, and peers (Gerend 
& Barley, 2009), as well as newspapers, magazines, youth clinics and their parents 
(Nandwani, 2010). Among university students, TV, magazines, the Internet and books 
serve as primary sources of information about HPV (Zeliha, 2014). Males in one study 
indicated that parents or guardians play a key role in influencing their decision to be 
vaccinated (Gutierrez et al., 2013). Differences in where men obtain their sexual health 
information varies – a study of young Australian males found that participants’ 
experience with STIs stemmed largely from their personal experience contracting an STI, 
and from “banter” among peers at school, while a study of males in the United States 
reported that participants were most likely to seek information about HPV on the Internet 
or from a healthcare provider (Nandwani, 2010).  
 
2.2 Messaging Strategies 
In terms of messaging strategies, it is suggested that gender-neutral promotions 
simplify the messaging effort required for a campaign (Schwartz, 2010). With the release 
of the HPV vaccine for females, parents in Australia and the UK were made aware of the 
availability of the HPV vaccine for girls by drug company advertising, but the same 
advertising has not been put into effect for the vaccination of males (Wilkinson, 2012). 
However, for health communication topics such as this, direct-to-consumer advertising 
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may not be as effective as other sources of messaging. Competing vaccine producers 
could provide mixed messages that take the focus of the larger picture of HPV prevention 
programs and vaccination importance (Schwartz, 2010), however, at this time only 
Gardasil is licensed for use in males, and mixed messaging is not a primary concern. 
Several studies have tested the messaging schemes of self-protection and partner 
protection to determine which, if either, is more effective at motivating vaccine 
acceptability among males. In Gerend and Barley’s study, which was conducted prior to 
approval for use of the HPV vaccine in males, interest in the vaccine did not differ by 
messaging scheme (2009). Predictability of intents to be vaccinated was similar to those 
found in later studies, however. Level of sexual activity, perceived susceptibility to HPV, 
perceived benefits of the vaccine, cost/difficulty of obtaining the vaccine, and perceived 
social norms surrounding vaccination were defined as factors influencing vaccine 
acceptability (Gerend & Barley, 2009).  
 It is important to distinguish between attitudes toward vaccination and 
intent to be vaccinated, particularly in discussions of messaging effectiveness. For 
instance, while the issue of protection against an incurable disease was a highly 
motivating factor for vaccination among both MSM and heterosexual males, intents to 
vaccinate were lower than attitudes toward vaccination for both groups (Gutierrez et al., 
2013). Variables showing significant correlation to intent to be vaccinated include: 
concern over side effects and vaccine safety, existing emphasis on the importance of 
vaccination, familiarity with the HPV vaccine, and knowledge of the importance of the 
HPV vaccine (Ferris et al., 2009). 
 With the release of the HPV vaccine for women, most campaigns utilized 
risk message frames to promote vaccination. Initial educational campaigns about HPV 
created a demand for the vaccine by creating a perception of high-risk among target 
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populations. HPV vaccine manufacturers used messaging strategies that empowered 
women, put them in control of their health decisions, and reduced anxiety about HPV and 
its related side-effects (Grantham et al., 2011). 
 
2.2.1 National Campaigns 
Because the HPV vaccine has been licensed for, and used in, females for nearly 
ten years, a significant amount of literature exists that discusses the initial marketing 
campaigns of vaccination makers Merck and GlaxoSmithKline to both promote their 
respective products and raise awareness about HPV in general. The latter campaigns, 
used to heighten awareness, are argued by some to have unfairly equated HPV with 
cervical cancer, thus creating a demand for a product that would not have otherwise 
existed. With the initial release of the vaccine to women, the media played a significant 
role in amplifying the messages produced by the vaccine manufacturers. Researchers 
have argued that the evolution of HPV as a serious issue in the media – a message likely 
catalyzed by Merck’s initial awareness campaign – played a significant role in vaccine 
uptake among females.  
 Merck’s “Tell Someone” campaign was released prior to FDA approval of 
Gardasil in 2006. While the manufacturer maintained that the campaign was released as a 
public service message to simply raise awareness about a serious health issue; the 
resulting media coverage, and the consequent approval of Gardasil by the FDA, has led 
many scholars to doubt this claim. 
 The “Tell Someone” campaign debuted in spring, 2006. The $107 million 
direct-to-consumer campaign included national commercials, a campaign specific 
website, and print (Landau, 2011). The commercials, which were unbranded, didn’t make 
any reference to cures or preventative strategies. Instead, they focused on several female 
 14
spokespersons from various ethnic backgrounds communicating their surprise at just 
learning that “cervical cancer is caused by certain types of a common virus. Cancer 
caused by a virus. HPV. Human Papillomavirus.” (funionsyeh1, 2010) The dialogue is 
scripted to emphasize HPV as a common virus. The call to action in the message is clear: 
tell someone, anyone, about HPV and its link to cancer. Men were not included in the 
“Tell Someone” campaign, which some have argued was misleading, stating that the 
campaign portrays a “limited course of health prevention under the guise of a public 
health campaign” (Landau, 2011). 
 In terms of raising awareness, “Tell Someone” was highly effective, 
increasing conversations about HPV in news outlets across the United States. Following 
the success of “Tell Someone” as an awareness campaign, and FDA approval of the HPV 
vaccine, Merck released a heavily branded one minute commercial focused on promoting 
Gardasil. The commercial, released in November 2006, reiterates concerns from the 
awareness campaign, stating that millions of women are diagnosed with cervical cancer 
each year. In contrast to “Tell Someone,” which featured women in an age range just 
outside of the recommended vaccine program (but within an age-range of mothers likely 
making vaccination decisions for their daughters), the “One Less” promotional campaign 
featured young female spokespersons likely in the catch-up age range (15-23). These 
young women were shown in a variety of settings and partaking in various activities, 
proclaiming that they could be “one less.” (modelinthecity, 2006) 
The young women in the “One Less” campaign are depicted as strong and 
independent, and their characters “appeal to mothers’ protective instincts and to teen 
girls’ desire for rebellion” (Branson, 2012). The messaging strategy of “One Less” 
utilizes a risk framing strategy that depicts potential loss (by not getting vaccinated, 
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women will get cervical cancer) but also provides a solution by empowering women to be 
vaccinated (Grantham et al., 2011). 
 In addition to the “Tell Someone” and “One Less” campaigns, Merck 
supported public health campaigns such as “Make the Connection,” a public education 
campaign sponsored by the Cancer Research and Prevention Foundation (“Make the 
connection”, 2006) and “Spread the Word, Not the Disease,” a similar public education 
campaign in Canada (Polzer & Knabe, 2012).  
 Merck created a media sensation with “Tell Someone,” making HPV a top 
health topic and concern among national media. News coverage on the topic of HPV 
following Merck’s campaigns is argued to have promoted an unfair positioning of the 
disease which de-stigmatized the virus through globalizing statements, which referred to 
the various strains of the virus as one and equated all with cervical cancer; comparisons 
with dissimilar diseases; and statistics (Polzer & Knabe, 2012). Additionally, the 
emphasis on adult women in “Tell Someone” presented a skewed perception of who can 
contract HPV while also equating amplifying the connection between HPV and cervical 
cancer (Landau, 2011). “One Less” continued the conversation, and was timed to ensure 
an equal (or greater) amount of news coverage to maximize message penetration among 
parents of females under 18, and among females 18-23. The promotion and branding of 
Gardasil in 2006 earned Merck “Brand of the Year Winner in 2006” by Pharmaceutical 
Executive (Branson, 2012). Unlike this major debut of the HPV vaccine for women, 
Merck has not released a national campaign promoting the HPV vaccine for men, which 
leads to questions over whether the initial campaigns targeted at women alienated the 
male population, and what messaging strategies would be effective in marketing to men.  
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2.2.2 News and Media Coverage 
Manufacturers of the HPV vaccine catalyzed the HPV conversation with nation 
campaigns, but news and media coverage of the topic served to disseminate and 
sensationalize the demand for vaccination among women in the early years of the 
vaccine’s release (Kata, 2010). Leading story lines like “Deaths from cervical cancer 
could jump fourfold to a million a year by 2050” (MacKenzie,2005), created a sense of 
dread among the public, but were quickly followed with hope from “soon-to-be-approved 
vaccines against the virus that causes most cases of cervical cancer” (MacKenzie, 2005).  
The topic of HPV, catalyzed by manufacturers and disseminated by traditional 
media, also spread across non-traditional and online media outlets. Initial content analysis 
of online sources of HPV and HPV vaccine information were largely rated as neutral or 
mostly positive, perhaps because, at this time, the general public was simply gathering 
information (Habel, Liddon & Stryker, 2009). An analysis of opinions of the HPV 
vaccine from males and females on the social media site MySpace found that men were 
more likely to share negative opinions that women (Keelan, Pavri, Balakrishnan & 
Wilson, 2010). YouTube, which was founded shortly before the licensure of the HPV 
vaccine, also became a popular forum for vaccine discussion. A 2008 study found that, 
while there was a higher percentage of videos with positive portrayals of the HPV 
vaccine (74.7%), the negative videos (25.3%) were more likely to be viewed and given 
higher star ratings (Ache & Wallace, 2008). A later study found that the largest 
percentage of videos with HPV related content produced on YouTube were from news 
sources, closely followed by user-generated videos, while less than 10% of videos were 
produced by medical centers or hospitals (Briones, 2010). 
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2.3 Summary  
 Similar discussions and evaluations of message framing strategies for the 
licensure of the HPV vaccine for use in males are limited. Manufacturers of the vaccine 
did not produce similar messaging campaigns for the new introduction of the vaccine, 
which has created a deficit in awareness that the vaccine even exists for men at all. 
Additionally, the primary promotional efforts used to increase awareness and vaccine 
uptake among women have led to the HPV vaccine being branded as a “girl’s vaccine.” 
 This study was developed to understand what promotional tactics and 
message framing strategies would be most effective in encouraging males to seek 
vaccination. It is assumed that young males in the primary age of initial vaccination (11-
13 years old) will require parental approval for vaccination, and strategies to promote 
vaccination to parents will be largely similar to those used previously in female 
vaccination programs. This study instead focuses on males in the catch-up age group (18-
26), who are responsible for making personal health decisions on their own. Using factors 
of intent to vaccinate, which have significant literature devoted to their understanding, 
this study seeks to understand what messaging strategies would be most effective for 




This study was designed to evaluate the effectiveness of vaccine promotion to 
males in the HPV vaccination program catch-up range (age 18-24). As mentioned 
previously, a multitude of literature exists which examines factors contributing to male 
perceptions and acceptance of the HPV vaccine, however, little research exists which 
actually tests the effectiveness of promotional strategies across various media.  
Two primary research questions informed the design of this study: 
RQ 1: What are males’ knowledge of and attitudes toward the HPV vaccine?  
RQ 2: What are the best messages and tactics for HPV vaccine promotion to 
males? 
Within this study, successfully answering the first research question would 
validate and confirm past research, laying a foundation for analyzing the messages and 
tactics of the second question. Answering the second question would provide guidance 
for the development of larger-scale evaluations, and campaigns specifically tailored to 
promote male vaccination programs. 
A survey questionnaire was developed for the purposes of this study, which can 
be found in Appendix A. Respondents accessed the survey online through a link 
distributed to students recruited from The University of Texas Department of Advertising 
student pool.  The use of an online survey allowed for an expedient response time and 
ease of distribution, both of which were deciding factors when choosing the method of 
administration for data collection.  
The questionnaire was divided into 4 parts: The first set of questions was 
designed to collect data to understand participants’ general health knowledge and sources 
of authority. Likert scale questions were used to determine how much value participants 
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placed on the opinions of peers, family, and healthcare providers, as well as the level of 
comfort they feel discussing topics of sexual health with others.  
The second set of questions was designed to collect data to understand 
participants’ knowledge and perceptions of HPV and the HPV vaccine. Previous studies 
found that low acceptance of the vaccine was often based on limited knowledge of HPV 
and related health risks (Crosby et al., 2011). True or false questions about vaccine 
approval and preventive intentions were used to determine whether participants 
understood the extent of HPV’s connection with various cancers and genital warts, as 
well as whether participants had been made aware of the availability of the vaccine for 
men. 
The third set of questions focused more closely on motivators for vaccine 
acceptance and sources of authority specifically sought out for information on HPV and 
the HPV vaccine. First, participants were asked whether they had received the vaccine. 
Those that had were specifically asked what their primary motivations were for receiving 
the vaccine. Options ranged from perceived personal risks, which are more likely to 
contribute to high vaccine acceptability (Brewer & Fazekas 2007), such as prevention of 
HPV contraction, prevention of genital warts and cancer to external factors, such as 
quelling the spread of the disease to future sexual partners. Participants that had not 
received the vaccine were give three questions which presented them with facts about 
HPV or the HPV vaccine. The first fact noted the approval of the vaccine for men for the 
prevention of genital warts and penile and anal cancers. The second fact used statistics, 
citing 1 million American men have genital warts caused by HPV. The third question was 
less factual, but notes the possibility that vaccinating males against HPV may also reduce 
incidences of HPV in females. Respondents were asked to rank how likely they were to 
receive the HPV vaccine in the next year after reading each fact.  
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 The fourth set of questions focused on the evaluation of two HPV vaccination 
promotions. Questions in this section used Likert scales to have participants rate how 
much attention they paid to each message, whether they concentrated on the messages, 
how much thought each message required to evaluate, and whether or not the messages 
were relevant to participants’ needs. Respondents also rated the strength, persuasiveness, 
importance and believability of the messages. 
 Two media selections were chosen for the evaluation of messaging tactics 
for HPV vaccine promotion among males. The first selection is a 30 second 
advertisement created and distributed by the CDC entitled “Close the Door to Cancer!” 
This immunization public service announcement, found on the CDC’s website (video link 
included in the questionnaire, found in Appendix A) is not specifically tailored to men, 
and may actually be better suited for parents of children (both male and female) ages 11-
12. The video was chosen, however, because it uses HPV related facts about the general 
population of the United States, and facts specifically affecting men to emphasize the 
importance of the HPV vaccine. The video opens with dramatic music and text that tells 
the viewer “Every year in the U.S. 14,000,000 people become infected with HPV” and 
later displays text that HPV causes “9,000 HPV-related cancers in MEN.” These “scare 
tactics” are similar to the sensational headlines used by media to sell the topic of HPV 
and related dangers when the vaccine was first licensed for use in females. 
 The second media selection is a promotional flier designed by The 
University of Maryland, and is highly targeted toward college-aged males. The flier, 
which can be viewed as part of the questionnaire in Appendix A, was selected in part 
because of availability (promotional materials specifically designed for men are limited), 
but also because the message specifically combats the possible perception among males 
that the HPV vaccine is a “girl’s vaccine.” For the purposes of this study, information 
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specifically related to The University of Maryland, including the University Health 
Center logo, tagline, and website, was redacted, so that participants would focus only on 
the message in the survey, not the source. 
 
3.1 Sample 
This study utilized a convenience sample, or non-probability sampling technique, 
due to restrictions of both time and resources. The study analyzed the results from 61 
completed surveys collected over a one month period. While all participants fell within 
the 18-26 age range, the majority of respondents were between the ages of 19 and 21. The 
majority (66.7%) of respondents identified as white/Caucasian, with 1.8% of participants 
identifying as African American, 11.1% as Hispanic or Latino, 18.5% as Asian or Pacific 
Islander, and 1.8% as biracial or multiracial. 85.2% of respondents identified as 
heterosexual, with the remaining 14.8% identifying as gay. 
 
3.2 Limitations 
Due to the restrictions of time and resources for this study, a relatively small 
convenience sample was collected. A sample of 61 respondents should be adequate for 
the statistical analysis of this study. The collection of survey responses could not be 
randomized for this study, which may affect the results. Additionally, the survey was 
distributed to males aged 18-26 attending The University of Texas, which may skew 
results as the knowledge and perceptions of this highly educated portion of the population 
may not be representative of similarly aged males that have not attended college. Further, 
the sensitive nature of this particular topic incurred a high dropout rate from the online 
survey. Finally, the selection of media for this study was limited due to the limited 
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The results of this study, presented below, are organized by the two primary 
research questions which guided this investigation.  
 
4.1 RQ 1: What are males’ knowledge of and attitudes toward the HPV vaccine?  
 The first half of this study discerned males’ understanding of HPV, HPV 
related health risks, and the HPV vaccine. It also confirmed primary sources of authority 
on health related topics, as described in previous research studies. 
 While the convenience sample of 61 males is comparatively small, it was 
sufficient to validate the findings of previous research studies. The majority of 
respondents indicated that they receive the majority of their health-related information 
from the Internet (75.9%), healthcare providers (72.2%), parents (55.5%) and peers 
(42.6%). Mass media sources, such as television (16.6%) and magazines (5.5%) ranked 
comparatively low as sources of authority on health-related topics.  
 Respondents were asked to rank the value they place on the opinions of 
others as well as the level of comfort they feel when discussing topics of health with 
peers, family, healthcare professionals, and significant others. Comfort level and value of 
opinion were ranked on a 5-point scale, with 1 indicating strong disagreement and 5 
indicating strong agreement. Participants indicated a high value of the opinions of 
healthcare providers (M = 4.33) and family members (M = 4.13), and a slightly higher 
than neutral value of the opinions of significant others (M = 3.67) and peers (M = 3.54). 
Participants also indicated a slightly higher than neutral level of comfort discussing topics 
of sexual health with healthcare providers (M = 3.74) and peers (M = 3.70), and a low 
level of comfort discussing such topics with parents (M = 2.74). 
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Table 2: Value of opinion and level of comfort when discussing topics of sexual health 
among sources of authority. 
   Value of Opinion Discussion Comfort Level 
Healthcare Providers 4.33 3.74 
Family/Parents 4.13 2.74 
Peers 3.54 3.70 
Almost all (92.6%) of respondents had heard of HPV. Respondents indicated 
healthcare providers, health classes, friends and the Internet as sources for first hearing 
about HPV. Knowledge of HPV varied, but was largely consistent with previous studies. 
 Participants were asked to identify basic facts about HPV, and health risks 
associated with the disease. Less than half of respondents were aware that there are 
numerous types of HPV (39%), though slightly more than half (64%) were aware that 
HPV is the most common sexually transmitted infection in the United States. Slightly less 
than half of respondents (57%) were aware that individuals with HPV do not often show 
symptoms, and that HPV can cause cancer. Two thirds of respondents (66%) connected 
HPV with cervical cancer; however, few were aware that anal cancer (25%) and penile 
cancer (28%) are also risks related to HPV. Slightly more than half of respondents were 
aware that HPV can cause genital warts (58%). Half of respondents believed women have 
a higher risk of contracting HPV than men. 
 Almost all respondents (85%) had heard of the HPV vaccine. The majority 
of respondents (75%) were aware that the HPV vaccine was available for both males and 
females; and had knowledge of FDA approval of the vaccine for use in men and women. 
Slightly less than half of respondents (42%) had received the vaccine. Respondents 
knowledge of the vaccine as a preventative for genital warts (60% aware), cervical cancer 
(64% aware) and anal/penile cancers (42% aware) was consistent with findings reported 
in previous studies.  
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 Of the respondents that had received the vaccine, almost all (91%) 
indicated that protection from HPV was their primary motivating factor for electing to be 
vaccinated. Protection against genital warts (39%), reduction of the spread of the virus to 
others (34%), and preventing cancer (21%) were also motivating factors for males that 
had been vaccinated. One respondent added the insight “why would I not receive a 
vaccine?” as a motivation.  
 
4.2 RQ 2: What are the best messages and tactics for HPV vaccine promotion to 
males? 
 Participants that had not been vaccinated were asked to respond to three 
messaging questions, ranking the likelihood of receiving the HPV vaccination in the next 
year after reading each message on a scale of 1 (not likely at all) to 10 (highly likely).  
 The first question appealed to the safety of the vaccine as a messaging 
strategy, using federal approval to promote the vaccine as safe for men. Respondents did 
not react significantly to this question (M = 5.23); only 35% of respondents were likely 
(indicating a ranking between 7 and 10) to receive the vaccine after receiving this 
information. 
 The second question used facts and fear appeal as a messaging strategy, 
indicating 1 million cases of American men suffering from genital warts as a result of 
contracting HPV. This tactic appeared to be the most positive in terms of responses in the 
7-10 range (42%), though reactions overall were not significant (M = 5.52). 
 The third question appealed to the reduction of HPV-associated disease 
among the female population as a result of the vaccination of the male population. This 
question received the most positive reaction overall (M = 5.62), though only 34% of 
respondents ranked in the 7-10 range.  
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All respondents were then asked to view a 30-second, fact-based public service 
announcement created by the CDC, and rate the message based on the level of attention, 
concentration, evaluation and relevance they felt it demanded (scale of 1-7). The message 
scored highest in the level of attention respondents paid to it (M = 4.84), and lowest in 
relevance to respondents needs (M = 4.13). Concentration (M = 4.25) and evaluation (M 
= 4.53) fell in expected ranges. 48% of students agreed that the message was informative 
(M = 3.64), and effective at conveying the intended message (M = 3.47), however 69% of 
respondents agreed that students are likely to ignore this type of message (M = 3.78). 
Ratings of message strength (M = 5.57), persuasion (M = 5.28), importance (M = 7.11) 
and believability (M = 6.87) were ranked mostly above average. Participants that had not 
yet been vaccinated were asked to rate (on a scale of 1-10) how likely they were to 
receive the HPV vaccination within the next year after viewing this message. Average 
responses (M = 4.53) indicated a low likelihood of future vaccination. 
Respondents then viewed the static print ad, and ranked it on the same scales as 
the public service announcement. Attention (M = 4.58) and evaluation (M = 4.22) were 
rated slightly lower than the CDC message, while concentration (M = 4.44) and relevance 
(M = 4.18) were rated slightly higher. Message strength (M = 5.12), persuasiveness (M = 
4.82), importance (M = 6.40) and believability (M = 6.00) all ranked lower than the CDC 
message. Participants that had not been vaccinated indicated a low likelihood of future 
vaccination (M = 4.33).  
Finally, respondents that had not yet been vaccinated prior to taking the survey 
were asked whether they were likely to receive the vaccine in the near future. 
Respondents that indicated they would not be seeking vaccination were asked to select 
from a predetermined list of reasons why they would still not seek vaccination. Cost of 
the vaccine, uncertainty about side effects or the specific effects of the vaccine on men, 
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and beliefs that the vaccine was not effective at preventing genital warts or cancer were 
common reasons for not seeking vaccination. Few respondents indicated the vaccination 
should be the responsibility of females. Additional comments given in response to this 
question further stated uncertainty about the vaccine, and safety in abstaining from sexual 
activity.  
 
Table 3: Comparison of messaging strategies. 
 :30s Video Print Ad 
Paid attention to message 4.84 4.58 
Concentrated on message 4.25 4.44 
Put thought into evaluating message 4.53 4.22 
Relevant to your needs 4.13 4.18 
Message Strength 5.57 5.12 
Message Persuasiveness 5.28 4.82 
Message Importance 7.11 6.40 
Message Believability 6.87 6.00 
I learned a lot from this message 3.64 2.82 
Message is effective for students 3.47 3.07 
This message changed my views 3.20 2.72 





Disseminating health-related information can be incredibly difficult in the modern 
day. Individuals have access to numerous sources of authority, each with varying levels 
of credibility, knowledge, and believability. Healthcare marketers and pharmaceutical 
industries promoting vaccines need to understand the importance their target audience 
places on each of these sources in order to successfully sell their product. In addition, 
they need to understand the level of existing knowledge the target population has in order 
to fill in gaps in information which would effectively convince individuals that the 
vaccine is worth seeking.  
This study sought to examine existing knowledge and perceptions of HPV and the 
HPV vaccine among males, and use this information to make suggestions for effective 
messaging strategies that will encourage males to seek vaccination. Several interesting 
conclusions can be drawn from this study, the most notable of which is that fact-based 
messaging is the most effective strategy for increasing vaccine acceptance and uptake 
among males. 
 While the majority of respondents had heard of HPV and were aware of 
the HPV vaccine, knowledge of HPV-related diseases was limited. These results were 
consistent with previously conducted studies by Crosby et al., and Blumenthal et al., and 
as such were expected. Messaging strategies that filled in this “knowledge gap” showed 
higher rates of improving intents to vaccinate. The fear appeal ranking question, which 
used the statistic that one million men suffer from genital warts as a result of contracting 
HPV, was the most effective of the three ranking questions used to determine the best 
overall tactic for vaccine promotion. 41% of respondents had previously indicated a lack 
of knowledge between the connection of HPV and genital warts – this question 
effectively bridged this knowledge gap and appealed to the target audience. Additionally, 
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the CDC public service message, which is largely fact-based, outperformed the static 
vaccination poster in almost every question. It was ranked highest on message 
importance, strength, persuasion and believability. While the strength of these scores 
might be attributed to the message source, it is also reasonable to assume the success of 
the message stems from the content, based on reactions to the previous tactic question. 
Based on the responses to questions about the effectiveness of the messages and whether 
students are likely to ignore these messages, it can be reasonably assumed that males in 
the catch-up age range are more concerned with informative messages than messages that 
seek to break the stereotype of the HPV vaccine as a “girl’s” vaccine.  
There are several continuing misconceptions and a lack of knowledge about 
health risks related to HPV that could be used in messaging strategies to further 
encourage males to seek vaccination. Respondents that had been vaccinated cited 
protection from HPV as their primary reason for seeking vaccination; few cited 
protection from cancers or genital warts as reasons for seeking vaccination. Messaging 
strategies that further connect HPV with genital warts and penile and anal cancers may be 
particularly effective. Perpetuating the connection of the vaccine with cancers will also 
be consistent with messaging from previous campaigns for females.  
Finally, in basic discussions of sources of authority among the surveyed group, it 
is interesting to note the differences between value of opinion and level of comfort 
expressed in each source. Among respondents, the opinions of healthcare providers were 
the most highly valued; healthcare providers were also ranked the source that respondents 
felt most comfortable engaging in conversations about sexual health. Parents and family 
members, while ranked second in terms of value of opinion, were ranked lowest in terms 
of conversation comfort level. Healthcare promotions often rely on spokespersons; 
understanding the existing relationships audiences have with particular sources of 
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authority will help to improve message receptivity and resonance. Future studies may 
further investigate the effectiveness of healthcare providers and parental figures as 
spokespersons in advertising to determine whether these are effective sources of authority 
in one-way messaging (such as commercials).  
Advertising for healthcare and health-related products has many opportunities for 
enhancing effectiveness. Further understanding sources of information and authority, as 
well as current knowledge of a population, can be used to increase both dispersion of 
messages to the target market, and resonance of the message. In the case of HPV 
vaccination programs, the majority of respondents indicated the Internet was a primary 
source of information for learning more about HPV and the HPV vaccination, however 
sources of Internet marketing are limited. Numerous sources of opinions on the subject of 
HPV can be found on the Internet, as evidenced in Ache & Wallace’s 2008 study, and 
Briones’ 2010 study, though future research may investigate where across the Internet 
males seek information, what the credibility of these sources is, and how they can be used 





Selecting the correct communication strategies and sources of authority for 
distributing messages is critical for all marketing communications, but can be more 
difficult for healthcare marketing because of the prevalence of opinions and sources of 
information available. Promotion of vaccine programs to young adults often occurs 
through recommendations from healthcare providers or through academic classes and 
institutional programs. The HPV vaccine lacks support through institutional programs 
because of the nature of STIs as a personal health risk, which makes alternate messaging 
strategies particularly critical.  
Lack of information about HPV and HPV related risks is a primary contributing 
factor to the low vaccine uptake among males in the vaccination catch-up age range. 
Currently, males’ primary motivation for seeking vaccination is to protect themselves 
from HPV; few males are aware of the connection between HPV and various cancers or 
genital warts. Messaging strategies that promote this connection through statistics and 
fear tactics may encourage an increase in vaccine acceptance.  
This study used a non-probability sampling technique to collect responses, which 
resulted in a respondent pool of highly educated individuals. The results of this study 
may vary if a random sampling technique were used, which is a notable limitation that 
can be addressed through further research. Future studies may find that a less educated 
population has a similar lack knowledge of HPV and related health risks, but is more 
affected by messaging strategies that emphasize cancer as a primary risk of HPV. 
Finally, further research may identify messaging strategies that not only provide 
key information about HPV and related health risks, but also keep the attention of the 
target audience. Male respondents in this study indicated lack of interest in both 
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messaging strategies presented, and ranked them as highly likely to be ignored by other 




APPENDIX A – SURVEY 
 
Demographics 
Please provide the following information about yourself: 






How do you usually describe yourself? 
 White/Caucasian 
 Black or African American 
 Hispanic or Latino 
 Asian or Pacific Islander 
 American Indian or Alaskan 
 Biracial or Multiracial 
 Other 
 
Do you identify as: 
 Heterosexual (straight) 
 Gay or Lesbian 
 Bisexual 
 Prefer not to answer 
 
General Health Knowledge / Sources of Authority 
From which of the following sources to you get the majority of your health-related 
information? (select all that apply) 






 Other family members  _______________ 
 Other _______________ 
 
For the following questions, please select the response that best describes how you feel. 
1. The opinions of my peers influence my personal health choices. 
Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
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2. The opinions of my parents/family influence my personal health choices. 
 Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
 
3. The opinions of healthcare professionals influence my personal health choices. 
 Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
 
4. The opinions of my significant other influence my personal health choices. 
 Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
 
5. I am comfortable discussing topics of sexual health with my medical care 
provider (family physician, doctor, nurse). 
Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
 
6. I am comfortable discussing topics of sexual health with my peers. 
Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
 
7. I am comfortable discussing topics of sexual health with my parents. 
Strongly disagree :_____:_____:_____:_____:_____:_____:_____: strongly agree 
 
Knowledge of HPV / HPV Vaccine 
8. Have you heard of HPV? (HPV stands for Human Papillomavirus) 
Yes / No 
 
9. If yes, where did you hear about HPV? 
 Private medical care provider (family physician, doctor, nurse) 
 Health Class 








10. Which of the following are true of the Human Papillomavirus (HPV) 
 There are many types of HPV 
 HPV is the most common sexually transmitted infection (STI) among sexually 
active people in the United States 
 Condoms provide full protection against HPV 
 Individuals with HPV do not often show symptoms 
 HPV can cause cancer 




11. Which of the following are risks related to HPV? 
 HPV can cause cervical cancer  
 HPV can cause anal cancer in men 
 HPV can cause penile cancer  
 HPV can cause genital warts 
 None of these are risks related to HPV 
 
12. Have your heard of the HPV Vaccine? 
Yes / No 
 
13. If yes, where did you first hear about the HPV Vaccine? 
 Private medical care provider (family physician, doctor, nurse) 
 Health Class 








14. Who is the HPV Vaccine for? 
 Males 
 Females 
 Both males and females 
 
Please mark the following statements true or false based on your existing knowledge 
of the Human Papillomavirus (HPV) and the HPV Vaccine. 
 
15. The HPV vaccine has been approved by the FDA (United States Food & Drug 
Administration). 
 
16. The HPV vaccine is approved for women. 
 
17. The HPV vaccine has been approved for men. 
 
18. The HPV vaccine prevents against genital warts. 
 
19. The HPV vaccine prevents against cervical and vaginal cancers. 
 





Promotional Messages / Sources of Authority / External Motivators 
21. Have you received the HPV vaccine? 
Yes / No 
 
If yes: 
What were your primary motivations for receiving the vaccination? (please check all that 
apply) 
 Protect myself from contracting HPV 
 Protect myself from genital warts 
 Protect myself from cancer 




The Human Papillomavirus (HPV) vaccine is approved for use in females, and has 
recently (in the last 5 years) been approved for use in males to prevent genital warts and 
penile and anal cancers.  Knowing this, how likely are you to receive the HPV 
vaccination in the next year? 
1 (not likely at all) – 10 (highly likely) 
 
Approximately 1 million American men have genital warts caused by HPV. An estimated 
2 out of every 1,000 men in the United States are newly diagnosed with genital warts 
annually. Knowing this, how likely are you to receive the HPV vaccination in the next 
year? 
1 (not likely at all) – 10 (highly likely) 
 
Vaccinating men against HPV may also effectively reduce HPV-associated disease in 
females. Knowing this, how likely are you to receive the HPV vaccination in the next 
year? 
1 (not likely at all) – 10 (highly likely) 
 
PARTICIPANTS VIEW :30s CDC ADVERTISEMENT “CLOSE THE DOOR TO 
CANCER!” (VIDEO LINKED FROM CDC WEBSITE; LINK INCLUDED IN 
APPENDIX) AND ANSWER THE FOLLOWING QUESTIONS ABOUT THEIR 
RESPONSE TO THE MESSAGE. 
http://www.cdc.gov/vaccines/cdcmediaresources/index.html?tab=2#TabbedPanels1  
Message Sensitivity Measure 
Please rate the message you just saw on the following scale. For example, on the first 
pair of adjectives if you thought the advertisement enticed you to pay attention, give a 
‘‘1.’’ If you thought the advertisement did not entice you to pay attention, give it a ‘‘7.’’ 
If you thought it was somewhere in between, give it a 2, 3, 4, 5, or 6. 
 
1. Paid attention to message:__1__:__2__:__3__:__4__:__5__:__6__:__7__: Did 
not pay attention to message 
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2. Concentrate on:__1__:__2__:__3__:__4__:__5__:__6__:__7__: Did not 
concentrate on 
3. Put thought into evaluating:__1__:__2__:__3__:__4__:__5__:__6__:__7__: No 
thought needed to evaluate 
4. Relevant to your needs :__1__:__2__:__3__:__4__:__5__:__6__:__7__:  Not 
relevant to your needs 
 
Directions: For the following questions, please select the response that best describes 
your opinion of the message(s). 
1=Strong Agree  2=Agree  3=Neutral  4=Disagree  5= Strongly Disagree 
 
5. I learned a lot from this message. 
6. This message would be effective for students my age. 
7. This message changed my views. 
8. Students my age generally ignore messages like this. 
 
Validity of the Message  
Directions: For the following questions, please select the response that best describes 
your opinion of the health message. 
 








If the respondent has not received the HPV vaccination: After watching this clip, how 
likely are you to receive the HPV vaccination in the next year? 
1 (not likely at all) – 10 (highly likely) 
PARTICIPANTS VIEW PRINT ADVERTISEMENT (INCLUDED IN 
APPENDIX) AND ANSWER THE FOLLOWING QUESTIONS ABOUT THEIR 
RESPONSE TO THE MESSAGE. 
Message Sensitivity Measure 
Please rate the message you just saw on the following scale. For example, on the first 
pair of adjectives if you thought the advertisement enticed you to pay attention, give a 
‘‘1.’’ If you thought the advertisement did not entice you to pay attention, give it a ‘‘7.’’ 
If you thought it was somewhere in between, give it a 2, 3, 4, 5, or 6. 
 
1. Paid attention to message:__1__:__2__:__3__:__4__:__5__:__6__:__7__: Did 
not pay attention to message 
2. Concentrate on:__1__:__2__:__3__:__4__:__5__:__6__:__7__: Did not 
concentrate on 
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3. Put thought into evaluating:__1__:__2__:__3__:__4__:__5__:__6__:__7__: No 
thought needed to evaluate 
4. Relevant to your needs :__1__:__2__:__3__:__4__:__5__:__6__:__7__:  Not 
relevant to your needs 
 
Directions: For the following questions, please select the response that best describes 
your opinion of the message(s). 
1=Strong Agree  2=Agree  3=Neutral  4=Disagree  5= Strongly Disagree 
 
5. I learned a lot from this message. 
6. This message is effective for students my age. 
7. This message changed my views. 
8. Students my age generally ignore messages like this. 
 
Validity of the Message  
Directions: For the following questions, please select the response that best describes 
your opinion of the health message. 
 








If the respondent has not received the HPV vaccination: After viewing this ad, how likely 
are you to receive the HPV vaccination in the next year? 
1 (not likely at all) – 10 (highly likely) 
 
Enduring Hesitations / HPV Vaccine Concerns 
If participant has not received the HPV Vaccine: 
For which of the following reasons would you choose not to receive HPV vaccine? 
(select all that apply) 
 It’s expensive 
 Harmful side effects 
 The vaccine is not 100% effective in preventing genital warts 
 The vaccine is not 100% effective in preventing cancers 
 It is more important for women to receive the vaccine than men 
 There is not enough information on the effects of the vaccine on men 
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